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Summary  42 
Background. Rates of hypertension treatment and control are low in China. Available 43 
and affordable medications are important for successfully controlling hypertension, 44 
but little is known about current patterns of access to and use of antihypertensive 45 
medications in Chinese primary health care.   46 
Methods. By using medication inventory data and prescriptions from a nationwide 47 
cross-sectional survey, we studied the availability, cost, and prescription patterns of 48 
62 antihypertensive medications at 3362 primary health care sites across 31 Chinese 49 
provinces. Site variation by geography and types were also evaluated. We also 50 
assessed the current use of high-value medications, defined as guideline-51 
recommended and low-cost. Finally, we evaluate the association of medication cost 52 
with availability and prescription patterns. 53 
Findings. Of 3362 sites, 8% stocked no antihypertensive medications; 34% stocked 54 
all four classes. Village clinics and sites in the western region had the lowest 55 
availability. Only 33% of all sites stocked high-value medications. Few high-value 56 
medications were prescribed (11% of all sites). Higher-cost medications were more 57 
likely to be prescribed than lower-cost alternatives.   58 
Interpretation. China has marked deficiencies in the availability, cost, and 59 
prescription of antihypertensive medications. High-value medications are not 60 
preferentially used. Future efforts to reduce the burden of hypertension, particularly 61 
through the work of primary health care providers, will need to improve access and 62 
use of antihypertensive medications, with particular attention to those with high value. 63 
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Research in context 69 
Evidence before this study 70 
 71 
We searched PubMed for literature in English and the China National Knowledge 72 
Infrastructure (CNKI) for literature in Chinese, published before May 2016, using the 73 
terms “primary health care”, “pharmaceutical policy”, “essential medication”, 74 
“essential medicine”, “hypertensive medication”, OR “hypertension”. We also 75 
reviewed the references from the identified articles and the highly relevant articles 76 
and reports. The awareness, treatment, and control of hypertension was found to be 77 
low. The National Essential Medicine Program, a “zero-profit” policy for essential 78 
medications, was implemented by all primary health care sites in 2009 to meet 79 
residents’ medication needs and reduce their out-of-pocket costs. However, 80 
conflicting results on availability and cost were found, and few studies reported 81 
prescription patterns of antihypertensive medications. Previous studies were limited to 82 
specific regions, populations, and data sources.   83 
 84 
Added value of this study   85 
 86 
We used a national primary health care study and a screening study of high risk for 87 
cardiovascular disease in China to depict the current status of availability, cost, and 88 
prescription patterns of antihypertensive medications in primary health care settings in 89 
China. We collected the data directly from primary health care sites, rather than 90 
analyzing secondary data from other reports. We found marked deficiencies in 91 
availability, cost, and prescription of hypertensive medications. Overall, 8% of 92 
primary health care pharmacies did not stock any antihypertensive medications. 93 
Village clinics and sites in the western region had the lowest availability. High-cost 94 
medications were more likely to be prescribed than low-cost medications. High-value 95 
medications, those that are guideline-recommended and low-cost, were not 96 
preferentially prescribed.  97 
 98 
Implications of all the available evidence  99 
 100 
Our findings suggest that interventions to improve hypertension treatment and control 101 
in China will need to ensure that antihypertensive medications area adequately 102 
available in primary health care settings. Implementation of the essential medicine 103 
policy at the local level is currently inadequate. Use of high-value medications may 104 
help to reduce the cost burden of hypertension treatment. 105 
  106 
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Introduction 107 
An estimated 200 million adults have hypertension in China, and fewer than 15% are 108 
treated.1-4 Moreover, among those who are treated, about two thirds do not achieve 109 
adequate blood pressure control.5-7 Inadequate management of hypertensive patients 110 
may have significant health and economic consequences: the sequelae of 111 
hypertension, including stroke and heart disease, are the leading causes of morbidity 112 
and mortality in China,8,9 and are associated with significant expense to patients and 113 
the health system.  114 
 115 
The successful mitigation of hypertension in China requires, in addition to lifestyle 116 
and behavioral modifications, that antihypertensive medications be made available 117 
and affordable, and that they be prescribed appropriately in primary health care (PHC) 118 
settings, a primary point of contact with the health system in China. Recent studies 119 
have suggested availability and high medication costs as major barrier to optimal 120 
utilization rates and adherence to essential antihypertensive medications, especially 121 
among low-income rural areas in China.10 122 
 123 
The Chinese health reform in 2009 strengthens role of PHC that serve as gatekeepers 124 
to the health care system.11 It also introduced the National Essential Medicine 125 
Program that was designed to “provide affordable and equitable basic health care for 126 
all by 2020.” The pharmaceutical policy has also evolved quickly in recent years, 127 
such as allowance for primary health care sites to procure non-essential medicines in 128 
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2014 and abolishment on the government price ceiling in 2015 (Appendix 1). While 129 
availability of medications may have increased after the National Essential Medicine 130 
Policy was launched,12-14 little is known about current patterns of access to 131 
antihypertensive medications across Chinese PHC settings, where higher financial 132 
burdens and limited medication choices may result in lower treatment and control 133 
rates. This information is essential for developing targets for interventions that are 134 
designed to improve national hypertension treatment and control. 135 
 136 
Accordingly, to address the need for information about the availability, cost, and 137 
prescription of antihypertensive medications in PHC settings across China, we 138 
analyzed data from a national, government-funded study of the PHC system and a 139 
large national cardiovascular screening project.15 Specifically, our study focused on 140 
examining the availability, cost, and prescription of antihypertensive medications at 141 
all four types of PHC sites in China. We then evaluated the availability of 142 
antihypertensive medications across PHC sites. Finally, we determined how the costs 143 
of antihypertensive medications were associated with the availability and prescription 144 
of antihypertensive medications, with a particular focus on lower-cost, guideline-145 
recommended treatments.  146 
 147 
Methods 148 
Data Source and Study Sample 149 
Data on the availability, cost, and prescription of antihypertensive medications were 150 
9 
 
derived from the China Patient-Centered Evaluative Assessment of Cardiac Events 151 
(PEACE) Million Persons Project (MPP) PHC Survey. The design of this nationwide 152 
survey, conducted from November 2016 through May 2017, has been described 153 
previously.16 Briefly, we established a nationwide epidemiologic collaborative 154 
network of the China PEACE MPP, which consists of 141 county/district-level 155 
regions from all 31 provinces in mainland China.15 The MPP enrolled the eligible 156 
study sites according to the number of residents of the catchment area, population 157 
stability, local economic conditions, and geographic location. The collaborative 158 
network therefore captures great diversity in geographic location, ethnicity of 159 
residents, economic development, and level of urbanization. The PHC services are 160 
provided by community health centres and community health stations (one level 161 
below) in urban areas, and township health centres and village clinics (one level 162 
below) in rural areas (Appendix 2). We surveyed 203 community health centres, 401 163 
community health stations, 284 township health centres, and 2474 village clinics to 164 
quantify the care-delivery capacity and the quality of PHC. The distribution of 165 
primary health care study sites sampled across rural and urban areas (township health 166 
centres/village clinics and community health centres/stations) reflects the national 167 
ratio.17  168 
  169 
Data on hypertension treatment and control rates were derived from the 170 
cardiovascular risk screening program of the China PEACE MPP, which to date has 171 
enrolled 1·7 million permanent residents, aged 35 to 75 years, who lived in 141 172 
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selected county-/district-level regions for at least 6 months in the past year. The 173 
interview data of China PEACE MPP included information about the history of 174 
hypertension diagnosis and treatment, collected by face-to-face administration of a 175 
questionnaire. In total, 1·09 million people with information in the MPP lived in the 176 
435 townships/communities that are the focus of this study. We linked the 177 
characteristics of PHC sites with local population epidemiologic data at the 178 
township/community level (i.e., one level below county/district), China’s 2015 179 
National Census data, and geographic location information (longitude and latitude) 180 
from a Chinese web mapping service (AMAP).18  181 
 182 
Data Collection and Definitions 183 
Pharmacy inventory. Lists of medications in stock at the time of the survey 184 
(November to December 2016) were obtained from each participating PHC site, 185 
copied, and reviewed. For each medication on the list, generic name, brand name, 186 
dosage form, specification, manufacturer, and retail price per sale unit were collected. 187 
We cleaned and checked the reported generic names against China Pharmacopoeia 188 
2015,19 achieving 95% in accuracy. 189 
 190 
Prescriptions. For outpatient prescriptions (April 2015 to March 2016), we collected 191 
each patient’s age, gender, and diagnosis, which are routinely on the prescriptions, as 192 
well as medication name, dosage, and administration. In PHC sites with an electronic 193 
prescription system, relevant information was directly imported into a digital 194 
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database. For sites without electronic prescription system, we included the first 100 195 
outpatient prescriptions in each 10-day period for the 12 months in our analysis (3600 196 
total prescriptions during the study period). We scanned copies, and trained staff 197 
manually abstracted relevant information, with double-entry methods as a quality 198 
check to ensure an accuracy standard of at least 98%. 199 
 200 
Blood pressure measurement, hypertension treatment, and control. In MPP, blood 201 
pressure was measured twice during the interview, using a unified electronic blood 202 
pressure monitor (Omron HEM-7430; Omron Corporation, Kyoto, Japan) and 203 
standardized procedures.20 Treatment rate was defined as the proportion of the 204 
hypertensive population who self-reported use of antihypertensive medications at the 205 
baseline interview in the China PEACE MPP population; control rate was defined as 206 
the proportion of the hypertensive population with a blood pressure <140/90 mm Hg 207 
at the baseline interview. Treatment and control rate of hypertension were measured 208 
by aggregating participant data at the township/community level. 209 
 210 
Site characteristics. We obtained information on characteristics of each PHC site, 211 
including workforce and use of information technology, through a survey of site 212 
leaders and health care professionals. 213 
 214 
Antihypertensive medications. We focused on 62 oral medications by generic names 215 
listed in the database of the China Clinical Guideline for Hypertension Management 216 
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2010 regardless of whether they were recommended,2,21 and the essential medicine 217 
lists.22,23 We placed each of these medications in one of eight mutually exclusive 218 
pharmacologic classes, including: (1) angiotensin-converting-enzyme inhibitors 219 
(ACEIs), (2) angiotensin-receptor blockers (ARBs), (3) beta-blockers, (4) calcium-220 
channel blockers (CCBs), (5) diuretics, (6) fixed-dose combination medications, (7) 221 
compound medications with ingredients from traditional Chinese medicine (TCM), 222 
and (8) centrally active drugs. Alpha-blockers and alpha-beta blockers were not 223 
included because of their scarcity in the primary care sector. 224 
 225 
We ascertained the availability of each antihypertensive medication in any dose in the 226 
site pharmacy, which was calculated as the proportion of all participating sites with a 227 
specific antihypertensive medication or medication class in stock. We calculated the 228 
annual median cost for each medication, using its median price across different PHC 229 
sites and the guideline-recommended dosage.  230 
 231 
We defined high-value medications as those that satisfied these two criteria: (1) the 232 
medication is recommended by the Chinese Guideline for Hypertension Management 233 
in Primary Health Care 2014,24, 25 and (2) annual medication cost of no more than 200 234 
RMB, a threshold corresponding to 1% of the average annual disposable income per 235 
capita in China in 2015. The guideline recommends medicines based on clinical 236 
effectiveness. We used the 2014 guideline as a framework to guide our investigation 237 
of a wider range of antihypertensive medications expected for routine use. 238 
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 239 
Statistical Analysis   240 
First, to examine availability, cost, and prescription of antihypertensive medications at 241 
different types of PHC sites, we calculated percentages for categorical variables, and 242 
mean and standard deviations or median and interquartile ranges (IQRs) for 243 
continuous variables, as appropriate. To determine site-specific characteristics 244 
associated with the availability of antihypertensive medications, we used a mixed 245 
model with township/community as random effects and a logit-link function. The 246 
model included a spherical covariate structure to account for spatial autocorrelation 247 
and differences among townships/communities. The final model included 6 248 
characteristics beside type of sites and regions, i.e. density of healthcare professionals, 249 
licensed physicians, physicians with a medical bachelor degree (5-year medical 250 
education), physicians who took continuing education course in the last year, social 251 
insurances for contracted healthcare professional, healthcare professionals who 252 
routinely use of IT system (Appendix 3a). 253 
 254 
Secondary, we modeled the prescribed medication as a function of its cost, both 255 
overall and rural/urban subgroups. To address potential sampling variation and 256 
imbalances in number between electronic and scanned-copy–abstracted prescriptions, 257 
we adapted a resampling approach to conducting a simulation analysis with a 258 
nonparametric bootstrap method.26,27 Specifically, for scanned-copy–abstracted 259 
prescription data, we randomly selected records with a sample size equal to the total 260 
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number of records; for electronic prescription data, we randomly selected a sample 261 
size equal to the sample size of the scanned-copy–abstracted prescription data. We 262 
then appended the two resampled datasets together and fitted the mixed model to 263 
estimate the association between the medication's prescription and its cost. We 264 
repeated this process 10,000 times to obtain the distributions of the estimated 265 
associations and their 95% confidential intervals (CIs).  266 
 267 
All analyses were conducted using SAS 9·4 (SAS Institute Inc., Cary, North 268 
Carolina). All statistical testing was 2-sided, at a significance level of 0·05. The Fuwai 269 
Hospital Institutional Review Board approved the study; the site survey was deemed 270 
exempt; informed consent was obtained from all MPP study participants. 271 
 272 
Role of funding source 273 
The funders of the study had no role in its design, data collection, data analysis, data 274 
interpretation, or writing of the report. The corresponding and lead authors had full 275 
access to all the data in the study, and all authors had final responsibility for the 276 
decision to submit for publication. 277 
 278 
Results 279 
Study Sample 280 
The study sample included 3362 PHC sites (18% urban, 82% rural) across China 281 
(Appendix 4). Site characteristics are shown in Table 1. Township health centres 282 
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constituted 8% of sites, village clinics 74%, community health centres 6%, and 283 
stations 12%.  284 
 285 
The 435 townships/communities, which collectively enrolled 1·09 million people in 286 
the China PEACE MPP, served as the study sample for determining hypertension 287 
treatment and control rates. The median sample size of participants at the 288 
township/community level was 2128 (IQR: 1165-3103). Participant characteristics are 289 
shown in Table 1. 290 
 291 
Availability, Cost, and Prescription Patterns of Antihypertensive Medications  292 
Among the 3362 centres, the availability of agents by class was 76% for CCBs, 63% 293 
for ACEIs, 60% for diuretics, 47% for beta-blockers, 34% for ARBs, and 10% for 294 
fixed-dose combinations (Table 2). The most commonly stocked medications in each 295 
class were nifedipine extended release (41%), captopril (44%), hydrochlorothiazide 296 
(35%), metoprolol (41%), valsartan (21%), and the fixed-dose combination of 297 
irbesartan and hydrochlorothiazide (6%) (Table 2). Compounds containing TCM were 298 
available in 56% of the PHC pharmacies. 299 
 300 
The pattern of medication availability varied by site. Overall, 8% of PHC pharmacies 301 
did not have any antihypertensive medications; 89% stocked either ACEIs/ARBs, 302 
beta-blockers, CCBs, or diuretics; and 34% had all four classes of medications (Figure 303 
1). 304 
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 305 
Availability, defined as having any class of medication, was associated with type of 306 
site and economic region (Appendix 5), and adjusted for other PHC–specific 307 
characteristics. Township health centres were more likely and sites in the western 308 
region were less likely to stock any kind of antihypertensive medication; village 309 
clinics and sites in the western region were also less likely to have all four classes 310 
(Figure 1). Urban sites prescribed ARBs more frequently than rural sites. Within rural 311 
and urban sites, however, there was substantial variation in the availability of 312 
medications, and no characteristic besides types of PHC sites and region was strongly 313 
associated with their availability (Appendix 3b). 314 
 315 
Individual medication median annual cost per patient varied substantially (Table 2). 316 
The median annual cost of the most-stocked medications in each of the most 317 
commonly used classes were nifedipine extended release (412 RMB), captopril (16 318 
RMB), hydrochlorothiazide (3 RMB), metoprolol (251 RMB), valsartan (663 RMB), 319 
and irbesartan and hydrochlorothiazide (1152 RMB). Figure 2 shows the medications 320 
in value quadrants, according to their guideline-recommended status and their cost. 321 
Only 33% of all sites stocked medications in the high-value care category. 322 
 323 
Across 396 townships/communities, we sampled 26,159 of 518,915 hypertension 324 
prescriptions. The most commonly prescribed individual medication was amlodipine; 325 
the most frequently prescribed medicine classes were CCBs (45%), ARBs (22%), 326 
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beta-blockers (10%), ACEIs (9%), and diuretics (5%) (Table 2). Overall, 86% of 327 
prescriptions were for one medication, whereas less than 1% were for three or more 328 
medications. When at least two medications were used, fixed-dose combinations 329 
(39%), ACEI plus CCB (18%), and ARB plus CCB (17%) were most commonly 330 
prescribed together (Appendix 6). In all, 2234 prescription records (8%) were for 331 
non–guideline-recommended medications, 3276 (11%) for high-value medications, 332 
and 23,603 (81%) for higher-cost, guideline-recommended medications (Figure 2). 333 
 334 
Treatment Rates and Hypertension Control Rates 335 
The sites varied by treatment and control rates (Appendix 7). The median risk-336 
standardized treatment and control rates were 35·6% and 8·3%, respectively. The 337 
worst 10% of sites had risk-standardized median treatment and control rates of 4·2% 338 
and 1·2%, respectively, whereas the best 10% had rates of 72·7% and 30·0%. 339 
 340 
Cost and Availability 341 
The cost of a medication was directly associated with being prescribed (Figure 3 and 342 
Appendix 8), but not with its availability (Figure 3). On average, higher-cost 343 
medications were more likely than lower-cost medications to be prescribed in PHC 344 
clinics. Lower-cost medications accounted for 40·5% of the medications in the 345 
pharmacies. Of all the prescriptions, 12·6% were for lower-cost medications and 346 
4·8% were for diuretics, the lowest-cost medication. 347 
 348 
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Discussion  349 
This national study of antihypertensive medications in China reveals marked 350 
deficiencies in the availability, cost, and prescription of antihypertensive medications. 351 
First, hypertension medications are inconsistently available in PHC pharmacies across 352 
China, and 1 in 12 pharmacies did not stock any antihypertensive medications. 353 
Second, despite the availability of low-cost antihypertensive medications, higher-cost 354 
medications were more often prescribed. In fact, the higher the cost of the medication, 355 
the more likely that it was prescribed. The higher-cost medications did not represent 356 
medications with higher efficacy.  357 
 358 
This study adds to the literature in important ways. It is the first national study of the 359 
availability, cost, and prescription of antihypertensive medications in China, involving 360 
all provinces. National policies with regard to essential medications and 361 
reimbursement may aim to improve access;28 this study provides a contemporary 362 
assessment of the availability and use of antihypertensive therapies in PHC sites 363 
around the country and shows that deficiencies exist at the point of care. This study 364 
has the distinct strength of being based on actual investigations of the pharmacies and 365 
inspection of the prescriptions. Conducting this evaluation required government 366 
support, partnership with PHC providers and administrators, and site access to inspect 367 
pharmacies and examine prescriptions. The study did not depend on reports from the 368 
sites but, rather, involved direct data collection. Previous studies were limited to 369 
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specific regions, populations, and data sources.14,29-32  370 
 371 
The reasons for gaps in the availability and prescription of antihypertensive 372 
medications are not clear. Chinese national policies dictate that essential medications 373 
should be available and affordable. However, we uncovered problems in the inventory 374 
of antihypertensive medication that can be supplied to patients at PHC sites. Despite 375 
the national focus on blood pressure control — and the responsibility of many of the 376 
sites for hypertension management33 — a significant proportion of these pharmacies 377 
either lacked any antihypertensive medication or had limited stocks, especially for 378 
lower-cost medications.13 One possible contributor to our finding that low-cost, high-379 
value medications are not frequently prescribed is the zero mark-up policy. Initiated 380 
in 2009, this policy prohibits health care providers from selling essential medicines at 381 
prices higher than their wholesale cost. This policy reportedly exerted a large net 382 
effect on the revenue of village clinics, despite increased government subsidies 383 
increased to compensate for revenue loss.34,35 Some have suggested that these reforms 384 
may have led to a less reliable drug supply system in China; for instance, village 385 
clinics, for instance, may no longer provide essential medicines at zero mark-up due 386 
to the lack of profit.36 With respect to drug prescribing patterns, there has been an 387 
increase in the use of expensive medications that are not covered by the policy since 388 
its implementation.10 Refinements to this policy may provide stronger incentives for 389 
the use of lower cost medications. Mandating the availability of medicines may not be 390 
sufficient to improve hypertension rates, but it is arguably a necessary component of 391 
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disease management programs. Additional studies are needed to carefully examine the 392 
impact from zero mark-up policies on access to antihypertensive medicines 393 
throughout Chinese primary healthcare centres.11,37 Also, some patients and doctors 394 
may prefer antihypertensive TCM, though its use was generally low in our study. 395 
 396 
The implications of this study for hypertension management in China are substantial. 397 
The reality of care delivery in the clinics is not consistent with the health needs of the 398 
nation, and the deficiencies in primary care pharmacies have implications for patient 399 
health, as evidenced by suboptimal treatment and control rates. As such, interventions 400 
to improve hypertension treatment and control will need to focus not only on 401 
bolstering education, screening, and protocols, but also on ensuring that 402 
antihypertensive medications are adequately stocked by PHC pharmacies.38 The 403 
adequacy of the medication inventory is not sufficient for progress in hypertension 404 
treatment and control, but it is certainly a fundamental component. Policymakers will 405 
need to grapple with why the aspiration of national policies is being stymied at the 406 
local level and, likely, thwarting efforts by practitioners to address hypertension in 407 
their patients. 408 
 409 
The study has some other important implications. The use of high-value medications, 410 
those that are guideline-recommended and reasonably priced, should be a priority for 411 
all countries but especially for those with limited resources.39 This study finds that 412 
high-value medications are not preferentially used in Chinese PHC settings, even as 413 
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the evidence for the greater efficacy of higher-priced medications is lacking.40 A 414 
greater emphasis on high-value antihypertensive medications has the potential to 415 
mitigate the cost burden of increasing the rates of treatment and providing more value 416 
to the country. In this respect, diuretics may be particularly cost-effective. Prior 417 
studies have suggested that drugs such as chlorthalidone may even be superior to 418 
drugs from other classes.23 In addition, too few comparative effectiveness studies of 419 
antihypertensive agents have been conducted,41 and it may be beneficial for China to 420 
prioritize these studies: by identifying the higher-priced medications with known 421 
marginal benefits over lower-cost alternatives, they would provide the basis for high-422 
quality, cost-efficient care.  423 
 424 
The availability of antihypertensive medications varied among types of sites and 425 
economic regions, but inadequacies were not confined to certain types of centres. Site 426 
characteristics were not strongly associated with the availability of antihypertensive 427 
medications. This finding indicates the need for a broad-based strategy that would 428 
address problems that almost all types of PHC centres throughout China face. 429 
 430 
The study has several limitations. First, the study sites are not a representative sample 431 
despite spanning the entire country geographically and being so large in number. The 432 
treatment and control rates, however, are very similar to national estimates.5 Second, 433 
we used a convenience sample and excluded people who were not permanent 434 
residents. Those who were excluded would likely have less access to care and would 435 
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likely have had even lower control rates. Nevertheless, any inaccuracies in this study 436 
would be a bias toward the null, suggesting that our findings might even 437 
underestimate the relationship. Of note, the prescription information reflects all 438 
prescriptions, including those provided to migrants. Third, this study focused on 439 
pharmacies in PHC sites, and people may go elsewhere for their prescriptions. 440 
However, half of private pharmacies impose fees that individuals must pay out of 441 
pocket.42 Therefore, we expect that most patients would have a strong preference to 442 
obtain their medications from the clinic pharmacy. Future studies should build on 443 
these and other emerging primary datasets in China to examine the association 444 
between access to antihypertensive medicines and clinical outcomes, including 445 
control rates. Fourth, our choice of the 200 RMB threshold for cost may be arbitrary, 446 
and it’s true that threshold of 1% of annual disposal income may be higher for rural 447 
populations. Applying a lower cost threshold however would further restrict the 448 
sample of medicines that could be defined as ‘high-value’, and may therefore lower 449 
the percentage of high-value drugs prescribed, further strengthening our findings. 450 
Finally, the inventory and prescription data that was collected covered slightly 451 
different time periods. If one assumes that any large-scale change in prescription drug 452 
inventories and prescribing behaviors are marginal over the span of several months, 453 
the impact on this study from similar, albeit non-overlapping time periods for data 454 
collection may be negligible. 455 
 456 
In conclusion, this study reveals key obstacles to progress in mitigating hypertension 457 
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in China. Despite advances in healthcare coverage and policy to limit financial risk 458 
and improve health outcomes,43 this study reveals deficiencies in the availability, cost, 459 
and prescription of antihypertensive medications. Future policies aimed at alleviating 460 
the burden of hypertension in China, particularly through the work of PHC providers, 461 
will need to improve access to high-value antihypertensive medications. 462 
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 632 
Figure 1: Availability of antihypertensive medicines by type of site and economic 633 
region 634 
Note: 635 
Data are shown in point estimates with 95% confidence intervals. 636 
Classification of the three economic regions is shown in Appendix 5. 637 
  638 
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 639 
640 
Figure 2: Availability and prescription of medications, by value quadrants 641 
Note: 642 
x-axis: Chinese Guideline for Hypertension Management in Primary Health Care 643 
2014.  644 
y-axis: Annual cost of medication per patient (RMB). 645 
  646 
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 647 
Figure 3: Association of annual cost per patient with availability and prescription 648 
pattern of antihypertensive medication  649 
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Table 1. Characteristics of primary health care sites and MPP population included by 650 
rural and urban area 651 
 Rural Urban 
Total Township 
health centre 
Village 
clinic 
Community 
health centre 
Community 
health station 
Primary health care site 
N 284 2474 203 401 3362 
Region (%) 
Eastern 28·5 27·8 38·9 56·4 31·9 
Central 31·0 39·8 29·1 15·7 35·6 
Western 40·5 32·4 32·0 27·9 32·5 
Linked MPP population (%) 
N 613638 478393 1092031 
Age, mean (SD) 56·2 (9·8) 55·8 (9·8) 56·0 (9·8) 
Female 59·6 60·9 60·1 
Ethnic Han 88.8 93.3 90.8 
12-year education or above 9·4 32·3 19·5 
Never smoked 11·8 16·3 13·8 
No insurance 0·2 1·1 0·6 
Last-year income >50K 8·6 18·3 12·8 
Hypertensive patients 46·4 44·1 45·4 
Awareness* 43·8 48·7 45·9 
Treatment* 27·1 34·5 30·3 
Control* 5·5 9·8 7·3 
* Among all hypertensive patients ·652 
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Table 2. Availability of individual and classes of medications among all primary 
health care sites  
 
Type Generic name 
EM list* Guidelines 
Availab
ility 
(%) 
(n=336
2) 
Class 
availab
ility 
(%) 
(n=336
2) 
Median annual 
cost (RMB) per 
patient  (IQR)  
Pres
cript
ion 
freq
uenc
y 
(%) 
W
HO 
NE
M 
PSE
M 
Guide
line in 
prima
ry 
health 
care 
2014 
JN
C 
8 
20
14 
Chine
se 
guidel
ine 
2010 
ACEI Captopril   1    44·0 62·6 16 (11-43) 2·5 
Enalapril   1    38·9 225 (160-435) 4·2 
Benazepril   13    8·4 1066 (748-1144) 1·2 
Ramipril 
  1    0·4 1819 (1819-
2021) 
0 
Perindopril 
  3    1·0 1255 (1172-
1261) 
0·2 
Fosinopril   7    3·6 1022 (723-1054) 0·7 
Lisinopril   2    3·3 659 (469-678) 0·1 
Quinapril 
  1    0·0 1166 (1166-
1166) 
<0·1 
Imidapril   1    0·3 - 0 
Cilazapril   0    0 - 0 
ARB Valsartan   15    21·4 34·4 663 (340-1028) 7·4 
Losartan   7    7·8 1306 (942-1883) 2·1 
Irbesartan   13    21·1 850 (610-1101) 6·7 
Candesartan   1    4·2 589 (468-751) 1·0 
Eprosartan   0    0 - 0 
Telmisartan   7    10·3 516 (298-801) 4·3 
Olmesartan 
  0    0·9 1833 (1761-
2660) 
0·2 
ACEI/A
RB 
 69·0 -  
beta-
blocker 
Bisoprolol   5    8·8 47·2 
 
791 (549-1080) 0·9 
Metoprolol   8    41·0 251 (171-281) 8·0 
Metoprolol extended 
release 
  0    3·6 438 (401-440) 0·2 
Atenolol   1    5·1 7 (5-8) 0·2 
Propranolol   2    7·6 26 (16-86) 0·0 
Betaxolol   0    0 - 0 
CCB Amlodipine   23    33·8 75·5 369 (206-565) 16·8 
Nifedipine   16    34·4 9 (5-19) 2·7  
Nifedipine extended 
release 
  0    41·2 413 (266-468) 7·4 
Nifedipine controlled-
release 
  0    15·0 1012 (890-1526) 6·0 
Felodipine extended 
release 
  15    19·2 425 (313-1049) 3·7 
Levamlodipine   9    11·8 688 (437-904) 7·7 
Nitrendipine   1    30·3 12 (7-44) 1·0 
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Type Generic name 
EM list* Guidelines 
Availab
ility 
(%) 
(n=336
2) 
Class 
availab
ility 
(%) 
(n=336
2) 
Median annual 
cost (RMB) per 
patient  (IQR)  
Pres
cript
ion 
freq
uenc
y 
(%) 
W
HO 
NE
M 
PSE
M 
Guide
line in 
prima
ry 
health 
care 
2014 
JN
C 
8 
20
14 
Chine
se 
guidel
ine 
2010 
Verapamil   4    1·4 302 (288-360) 0 
Verapamil extended 
release 
  0    0·0 - 0 
Diltiazem   11    1·9 507 (269-1117) 0 
Diltiazem extended 
release 
  0    0·7 583 (527-869) 0·1 
Lacidipine   7    4·0 228 (225-273) 0·3 
Nicardipine   1    0 - 0 
Benidipine   0    0·1 - 0 
Lercanidipine   0    0·3 - 0 
Diuretic
s 
Indapamide   1    32·6 59·9 42 (18-99) 1·2 
Indapamide extended 
release 
  0    12·6 279 (197-389) 1·3 
Hydrochlorothiazide   1    34·7 3 (1-5) 1·0 
Bendroflumethiazide   0    0 - 0 
Chlorthalidone   0    0 - 0 
Spironolactone   2    22·3 41 (28-56) 0·5 
Furosemide    1    14·1 17 (16-25) 0·5 
Triamterene   1    3·3 115 (58-158) 0 
Amiloride 
hydrochloride 
  0    1·2 232 (232-232) 0 
Compo
und 
containi
ng TCM 
ingredie
nts† 
Compound reserpine t
riamterene 
  1    36·6 55·6 414 (299-435) 2·7 
Compound reserpine   1    34·9 80 (54-158) 0·6 
Compound 
dihydralazine sulfate 
  2    1·2 137 (137-158) <0·1 
Compound trizin and 
rutinum 
  1    0·1 - 0 
Compound kendir   1    2·5 65 (63-194) 0 
Zhenju jiangya tablet   7    8·2 178 (130-269) 0·8 
Fixed-
dose 
combin
ation 
Amiloride compound   2    0·1 10·4 116 (116-116) <0·1 
Losartan potassium 
and 
hydrochlorothiazide 
  1    2·7 1983 (895-2427 1·6 
Valsartan and 
hydrochlorothiazide 
  0    1·2 3750 (1726-
4720) 
<0·1 
Irbesartan and 
hydrochlorothiazide 
  1    6·1 1136 (805-1609) 3·1 
Captopril 
hydrochlorothiazide 
  6    5·5 147 (66-197) 0·2 
Nitrendipine atenolol   0    0 - 0 
Centrall
y active 
Verticil   1    0·1 2·3 
 
588 (588-588) 0·1 
Clonidine   2    1·5 - 0 
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Type Generic name 
EM list* Guidelines 
Availab
ility 
(%) 
(n=336
2) 
Class 
availab
ility 
(%) 
(n=336
2) 
Median annual 
cost (RMB) per 
patient  (IQR)  
Pres
cript
ion 
freq
uenc
y 
(%) 
W
HO 
NE
M 
PSE
M 
Guide
line in 
prima
ry 
health 
care 
2014 
JN
C 
8 
20
14 
Chine
se 
guidel
ine 
2010 
drugs Reserpine   15    0·4 45 (45-45) 0·2 
Data are number, median (IQR) or %. IQR: interquartile ranges 
* Essential lists: 
WHO: WHO Model Lists of Essential Medicines 
NEM: National Essential Medicine List 
PSEM: provincial supplementary essential medicine lists (value refers to the number of provinces that 
had this medication in its provincial list) 
† Ingredients per tablet for compound containing TCM: 
Compound reserpine triamterene: reserpine 0·1 mg, triamterene 12·5 mg, hydrochlorothiazide 12·5 mg, 
dihydralazine 12·5 mg 
Compound reserpine: reserpine 0·032 mg, hydrochlorothiazide 3·1 mg, dihydralazine 4·2 mg, 
promethazine 2·1 mg 
Compound dihydralazine sulfate: dihydralazine sulfate 10·0 mg, hydrochlorothiazide 12·5 mg, 
reserpine 0·1 mg 
Compound trizin and rutinum: hydrochlorothiazide 2·0 mg, dihydralazine sulfate 1·5 mg, rutinum 5·0 
mg, reserpine 0·03 mg 
Compound kendir: kendir 220 mg, dihydralazine sulfate 1·6 mg, hydrochlorothiazide 1·6 mg, 
promethazine 1·05 mg 
Zhenju jiangya tablet: clonidine 0·03 mg, hydrochlorothiazide 5·0 mg 
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Appendix 1. Major policies about essential medications’ availability and 
affordability since 2009 
 
Chinese health reform in 2009 introduced the National Essential Medicine Program 
that was designed to “provide affordable and equitable basic health care for all by 
2020.” It includes: 1) introduction of a national essential medicine list at primary 
health care level; 2) establishing province-based competitive-bidding system; 3) 
dispensing of essential medicines at zero mark-up, and 4) reimbursement mechanism 
by health insurance. The pharmaceutical policy has also evolved quickly in recent 
years, major policies about essential medications’ availability and affordability since 
2009 are shown as follows: 
Year Department Policy 
2009 MOH Opinion on establishing essential medicine regime 
MOH National Essential Medicine List (2009) 
CFDA Notice on strengthening production and quality monitoring in 
essential medicines 
MIIT Notice on strengthening in supply of essential medicines 
MOH; NDRC; 
MOF 
Working specification in medicine procurement 
2010 State council The guidance in establishing and normalizing the medicine 
procurement mechanism among government-sponsored 
primary health care sites 
MOH National Essential Medicine List (2012) 
2012 MIIT Fixed-point production in medicines with small dosage but 
essential for clinical treatment 
8 Ministries1 Opinion on ensuring the supply of the commonly-used low-
cost medicines 
2014 NHFPC Opinion on strengthening the storage and use of medicines 
among primary health care sites  
7 Ministries2 Notice in promoting the price reform of medicines 
Abbreviations: 
MOH: Ministry of Health 
CFDA: China Food and Drug Administration 
MIIT: Ministry of Industry and Information Technology 
NDRC: National Development and Reform Commission 
NHFPC: National Health and Family Planning Commission 
MOF: Ministry of Finance 
MHRSS: Ministry of Human Resources and Society Security 
MOC: Ministry of Commerce 
CFDA: China Food and Drug Administration 
SATCM: State Administration of Traditional Chinese Medicine 
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Note: 1: including NHFPC, NDRC, MIIT, MOF, MHRSS, MOC, CFDA, SATCM; 2: including NDRC, 
NHFPC, MHRSS, MIIT, MOF, MOC, CFDA  
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Appendix 2. A brief introduction of the health system in China 
 
Organization 
Health service institutions in China include hospitals, primary health care (PHC) 
institutions and specialized public health institutions (Appendix Figure 1). The 
primary health care system in China is divided into urban and rural components, 
which are organized differently. Urban areas include community health centres and, 
one level below them, community health stations (i.e. local clinics). Rural areas 
include township health centres and, one level below them, village clinics. In 2016, 
primary health care institutions comprised of 94% of all health care institutions. 
 
Management 
The administration and management relationship between PHC institutions is 
relatively complex. For example, urban community health stations can either be 
affiliated with community health centres in the same community, or independent from 
them; in the latter case, however, the health stations may still receive technical 
support from the health centres. Similar to health stations in the urban areas, village 
clinics can be either affiliated with the rural township health centres, or independent 
from them. In some circumstances, village clinics can be private health institutions 
that do not fall within the government budget plan. In general, the national and local 
government health departments supervise and administer the PHC institutions. 
Professional disease prevention institutions such as the Center for Disease Control and 
Prevention (CDC) provide technical support and guidance. 
 
Services 
Primary health care institutions in China are responsible for providing both basic 
clinical care and public health services to local residents. In 2015, they provided 4.1 
billion outpatient visits and 40.3 million hospitalizations, which accounted for 55.6% 
and 19.2% of the total utilization in the health care system. They are also the main 
executor of the National Essential Public Health Service Program aiming to provide 3 
categories and 12 subcategories of basic public health services to all residents for free. 
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Organization of the health system in China 
 
Source: This figure is cited from Meng Q et al.: People's Republic of China Health System Review; 
2015. We used the original figure with the authors’ permission. 
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Appendix 3a. Definition of six site-specific characteristics 
 
Site-specific characteristics Definition 
Density of healthcare professionals* Total number of healthcare professionals per 10,000 residents 
Licensed physicians  Proportion of primary physicians who are licensed among all 
healthcare professionals 
Physicians with medical bachelor degree  Proportion of physicians who have a medical bachelor degree (i.e. 
with at least 5-year medical education in medical school) 
Physicians took continuing education 
causes in the last year 
Proportion of physicians who have taken continuing education 
courses in the last year 
Social benefits for contracted healthcare 
professionlas 
Number of social benefits for contracted healthcare professionals 
(i.e. those professionals without permanent position)  
Healthcare professionals who use IT 
system routinely†  
Proportion of healthcare professionals who use IT systems† routinly  
Note: 
*Healthcare professionals include physicians, public health workers and nurses who work in the 
primary health care setting; †IT: Information technology 
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Appendix 3b. Association of availability with site type, economic region and sit-
specific characteristics 
 
 Adjusted odd ratio 
(95% CI) 
Type of site  
Rural township health centre 1 
Urban community health station 0.35 (0.12-1.02) 
Urban community health centre 0.15 (0.05-0.40) 
Village clinic 0.35 (0.14-0.89) 
Region  
Central 1 
West 0.34 (0.13-0.89) 
East 1.21 (0.47-3.11) 
Site characteristics  
Total number of healthcare professionals per 10,000 
residents* 
1.02 (0.99-1.04) 
Proportion of physicians who are licensed 0.98 (0.97-0.99) 
Proportion of physicians with medical bachelor degree 0.95 (0.92-0.98) 
Proportion of physicians who took continuing education 
courses in the past year 
1.43 (1.24-1.65) 
Number of social benefit schemes for contracted healthcare 
professionals 
1.00 (1.00-1.00) 
Proportion of healthcare professionals who use IT systems 
routinely† 
1.02 (1.01-1.02) 
Note: 
*Healthcare professionals include physicians, public health workers and nurses who work in 
the primary health care setting 
†IT: Information technology 
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Appendix 4. Flowchart of study participant selection 
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Appendix 5. List of provinces by economic regions 
 
Eastern region includes 11 provinces and municipalities: Beijing, Tianjin, Hebei, 
Liaoning, Shanghai, Jiangsu, Zhejiang, Fujian, Shandong, Guangdong, and Hainan. 
Central region includes 8 provinces: Shanxi, Jilin, Heilongjiang, Anhui, Jiangxi, 
Henan, Hubei, and Hunan. 
Western region includes 12 provinces, autonomous regions and municipalities: 
Inner-Mongolia, Chongqing, Guangxi, Sichuan, Guizhou, Yunnan, Tibet, Shannxi, 
Gansu, Qinghai, Ningxia, and Xinjiang. 
 
Distribution of three economic regions is shown as the following figure: 
 
Note: 
Eastern region (grey); Central region (navy); Western region (mazarine) 
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Appendix 6. Treatment pattern by type of primary health care site 
 
 Total Township 
health centre 
Community 
health centre 
Anti-HTN medication record number 29,171 18,993 10,178 
Overall (%)*    
ACEI 9·1  6·0  14·9  
ARB 21·7  24·7  163  
β-blocker 9·4  10·4  7·6  
CCB 45·6  46·8  43·4  
Diuretic 4·7  3·1  7·7  
Compound containing TCM 4·2  2·2  8·0  
Fixed-dose combination 4·9  6·9  1·3  
CAD 0·3  0·0  0·9  
HTN prescription number 26,159 17,752 8407 
Monotherapy (%)† 86·2  88·2  81·9  
ACEI 7·9  5·7  12·7  
ARB 23·5  26·4  16·9  
β-blocker 9·3  10·6  6·4  
CCB 49·8  51·9  45·2  
Diuretic 4·2  3·0  7·0  
Compound containing TCM 4·9  2·5  10·5  
CAD 0·4  0·0  1·2  
Two medicines (%)† 13·0  11·2  16·8  
ACEI plus CCB 18·3  8·1  32·8  
ARB plus CCB 17·0  12·4  23·5  
ACEI plus Diuretic 2·2  0·8  4·2  
ARB plus Diuretic 2·1  1·3  3·3  
CCB plus Diuretic 3·5  1·5  6·2  
CCB plusβ-blocker 9·3  7·9  11·4  
Fixed-dose combination 38·9  61·9  6·4  
ACEI plus ARB 0·4  0·3  0·6  
Three or more medicines (%)† 0·8  0·6  1·3  
ACEI/ARB plus CCB plus Diuretic 12·7  8·6  16·8  
ACEI/ARB plus CCB+Diuretic plusβ-blocker 2·8  1·9  3·7  
Note: 
* Use Anti-HTN medication record number as denominator. The results of the following subcategory of 
medication use were the proportion among in certain treatment pattern 
† Use HTN prescription number as denominator. The results of the following subcategory of medication 
use were the proportion in this certain treatment pattern 
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Appendix 7. Distribution of risk-standardized treatment and control rates 
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Appendix 8. Distribution of coefficients in Figure 3a 
 
 
Note: Analysis is based on 10,000 times of simulation. 
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Appendix 9. The Members of Provincial Coordinating Office in China PEACE Million Persons Project 
 
Beijing Center for Diseases Prevention and Control: Chun Huang, Bo Jiang; Tianjin Chest Hospital: Zhigang Guo, YingYi Zhang; Hebei Center for 
Diseases Prevention and Control: Jingbo Zhai, Yuhuan Liu; Shanxi Center for Diseases Prevention and Control: Zhikai Chai, Yaqing Meng; Inner 
Mongolia Center for Diseases Prevention and Control: Namuheng, Yunfeng Xi; Liaoning Center for Diseases Prevention and Control: Chunming Lu, 
Ning Li, Leilei Pan; Jilin Center for Diseases Prevention and Control: Jianwei Liu, Yao Fu, Ting Liu; Heilongjiang Center for Diseases Prevention and 
Control: Shichun Yan, Lin Zhan; Shanghai Center for Diseases Prevention and Control; Jiangsu Center for Diseases Prevention and Control: Jinyi 
Zhou, Yu Qin; Zhejiang Hospital: Wei Yu, Xiaoling Xu, Li Yang; Anhui Center for Diseases Prevention and Control: Zhirong Liu, Luan Zhang; Fujian 
Center for Diseases Prevention and Control: Shuguang Lin, Xin Fang; Jiangxi Center for Diseases Prevention and Control: Liping Zhu, Yan Xu; 
Shandong Center for Diseases Prevention and Control: Xiaolei Guo, Junli Tang; Henan Center for Diseases Prevention and Control: Gang Zhou, Lei 
Fan; Hubei Center for Diseases Prevention and Control: Shuzhen Zhu, Junfeng Qi; Hunan Center for Diseases Prevention and Control: Biyun Chen, 
Li Yin; Guangdong Center for Diseases Prevention and Control: Yingqing Feng, Xida Li; The First Affiliated Hospital of Guangxi Medical University: 
Hong Wen; Hainan Center for Diseases Prevention and Control: Dan Wang, Puyu Liu; Chongqing Center for Diseases Prevention and Control: Wenge 
Tang, Xianbin Ding; Sichuan Center for Diseases Prevention and Control: Ying Deng, Jun He, Xiaoqi Gao; The People’s Hospital of Guizhou Province: 
Guie Liu, Chenxi Jiang; Yunnan Center for Diseases Prevention and Control: Shun Zha, Cangjiang Yang; Tibet Center for Diseases Prevention and 
Control: Guoxia Bai, Yue Yu; Shaanxi Center for Diseases Prevention and Control: Jingang Ma, Rong Liu; Gansu Center for Diseases Prevention and 
Control: Xinhua Wang, Tingcai Wang; Qinghai Center for Diseases Prevention and Control: Minru Zhou, Xiaoping Li; Ningxia Center for Diseases 
Prevention and Control: Jianhua Zhao, Shaoning Ma; The First Affiliated Hospital of Xinjiang Medical University: Yitong Ma, Ying Huang, Yuchen 
Zhang; Xinjiang Corps Center for Diseases Prevention and Control: Fanka Li, Jiacong Shen. 
 
 
